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Thank you for your comment.
In this paper, we reported our own experience with diphenyl-
hydantoin (DPH). On the basis of this experience, as well as the
wide literature search that we conducted, we personally believe
that DPH is superior to the most widely used medication (Diazox-
ide) in suppressing insulin secretion, Refs. [1,2]. Our article is pub-
lished in the category of a Case Report, based upon personal
experience, and is not intended to generate recommendations or
guidelines. We suggest considering DPH as a temporary therapeu-
tic measure in the preoperative period of patients with insulinoma,
as well as an alternative measure for inoperable insulinomas,
something that has already been successfully done by others [3,4].1877-5934  2009 International Journal of Diabetes Mellitus. Published by Elsevier Ltd.
doi:10.1016/j.ijdm.2009.12.004
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